Article Text

PDF
The BRCA1 c.5434C→G (p.Pro1812Ala) variant induces a deleterious exon 23 skipping by affecting exonic splicing regulatory elements
  1. Pascaline Gaildrat1,
  2. Sophie Krieger2,
  3. Jean-Christophe Théry1,
  4. Audrey Killian1,
  5. Antoine Rousselin2,
  6. Pascaline Berthet3,
  7. Thierry Frébourg1,4,
  8. Agnès Hardouin2,
  9. Alexandra Martins1,
  10. Mario Tosi1
  1. 1Inserm U614, Faculty of Medicine, University of Rouen, IFRMP, Rouen, Institute for Biomedical Research, Rouen, France
  2. 2Laboratoire de Biologie Clinique et Oncologique, Centre François Baclesse, Caen, France
  3. 3Consultation d'Oncogénétique, Centre François Baclesse, Caen, France
  4. 4Department of Genetics, University Hospital, Rouen, France
  1. Correspondence to Mario Tosi, Inserm U614, Faculty of Medicine, 22 Boulevard Gambetta, 76183 Rouen, France; Mario.tosi{at}univ-rouen.fr

Abstract

Background A large fraction of the sequence variants of unknown significance or unclassified variants (UVs) could be pathogenic by affecting mRNA splicing. The breast and ovarian cancer susceptibility gene BRCA1 exhibits a large spectrum of sequence variation but only two variants, both located in exon 18, have been shown experimentally to affect splicing regulatory elements. The present study investigated the impact on splicing of the variant BRCA1 c.5434C→G (p.Pro1812Ala), identified in an ovarian cancer patient. This variant has previously been studied at the protein level with inconclusive results concerning its pathogenic role.

Methods Analysis of RNA from patient peripheral blood was performed by RT-PCR. The effect of the variant was tested by using splicing reporter hybrid minigene assays.

Results Using patient RNA analyses and hybrid minigene assays, we showed that this variant induces a major splicing defect, with skipping of exon 23, resulting in frameshift and predicted protein termination within the second BRCT domain. Moreover, we showed that the segment c.5420–5449 of BRCA1, in the centre of exon 23, exhibits splicing enhancer properties. This enhancement is abolished by the c.5434C→G mutation, indicating that the nucleotide change, in this highly conserved region, affects a splicing regulatory element. Bioinformatics analyses predict that the mutation c.5434C→G creates an hnRNPA1 dependent splicing silencer.

Conclusion These data, together with segregation data, argue for the classification of BRCA1 c.5434C→G as a pathogenic splicing mutation. These results also suggest that UVs in highly conserved nucleotide sequences of short exons may be good candidates for detecting functionally relevant splicing regulatory elements.

  • Genetic screening/counselling
  • molecular genetics
  • breast cancer

Statistics from Altmetric.com

Footnotes

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the Centre de Lutte Contre le Cancer François Baclesse, Caen, France.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.